Asgharpour Amon, Dinani Amreen, Friedman Scott L
Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Transl Gastroenterol Hepatol. 2021 Jan 5;6:5. doi: 10.21037/tgh.2020.01.04. eCollection 2021.
Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are highly prevalent forms of chronic liver diseases globally, associated with rising all-cause morbidity and mortality. While distinct diseases, NAFLD and ALD share several similarities; both can result in fatty liver disease, steatohepatitis, associated hepatic fibrosis and cirrhosis-related complications, including hepatocellular carcinoma (HCC). Our understanding of the pathophysiology and manifestations of these diseases has advanced significantly, which has established a new foundation to identify therapeutic targets and test new treatments. This review underscores emerging pathogenic pathways that establish a template for target identification and clinical trials. Success is critically dependent upon productive interactions between academic investigators and industry to address unmet therapeutic needs in NAFLD and ALD.
非酒精性脂肪性肝病（NAFLD）和酒精性肝病（ALD）是全球范围内高度流行的慢性肝病形式，与全因发病率和死亡率的上升相关。虽然是不同的疾病，但NAFLD和ALD有几个相似之处；两者都可导致脂肪性肝病、脂肪性肝炎、相关的肝纤维化和肝硬化相关并发症，包括肝细胞癌（HCC）。我们对这些疾病的病理生理学和表现的理解有了显著进展，这为确定治疗靶点和测试新疗法奠定了新基础。本综述强调了新兴的致病途径，这些途径为靶点识别和临床试验建立了模板。成功与否关键取决于学术研究人员和产业界之间富有成效的互动，以满足NAFLD和ALD中未满足的治疗需求。
